Associations of Three-Dimensional Anthropometric Body Surface Scanning Measurements and Coronary Artery Disease
Open Access
Abstract
Background and Objectives: The relationship between three-dimensional (3D) scanning-derived body surface measurements and biomarkers in patients with coronary artery disease (CAD) were assessed. Methods and Methods: The recruitment of 98 patients with CAD confirmed by cardiac catheterization and 98 non-CAD patients were performed between March 2016 and December 2017. A health questionnaire on basic information, life style variables, and past medical and family history was completed. 3D body surface measurements and biomarkers were obtained. Differences between the two groups were assessed and multivariable analysis performed. Results: It was found that chest width (odds ratio [OR] 0.761, 95% confidence interval [CI] = 0.586–0.987, p = 0.0399), right arm length (OR 0.743, 95% CI = 0.632–0.875, p = 0.0004), waist circumference (OR 1.119, 95% CI = 1.035–1.21, p = 0.0048), leptin (OR 1.443, 95% CI = 1.184–1.76, p = 0.0003), adiponectin (OR 0.978, 95% CI = 0.963–0.994, p = 0.006), and interleukin 6 (OR 1.181, 95% CI = 1.021–1.366, p = 0.0254) were significantly associated with CAD. The combination of biomarker scores and body measurement scores had the greatest area under the curve and best association with CAD (area under the curve of 0.8049 and 95% CI = 0.7440–0.8657). Conclusions: Our study suggests that 3D derived body surface measurements in combination with leptin, adiponectin, and interleukin 6 levels may direct us to those at risk of CAD, allowing a non-invasive approach to identifying high-risk patients.Keywords
Funding Information
- Chang Gung Medical Foundation (CMRPG2F0081, CMRPG2F0082, CMRPG2F0083, CMRPD3F0021, CMRPD3F0022, CMRPD3F0023, NARPD3J0021, NARPD3J0022, NARPD3L0061, 108-2410-H-182-008-MY2, 110-2410-H-182-013-MY3, WJY 2020-HR-01, WJY 2021-HR-01, WJY 2022-HR-01, WYJ 2021-AP-01, WYJ 2022-AP-01)
- Ministry of Science and Technology, Taiwan (CMRPG2F0081, CMRPG2F0082, CMRPG2F0083, CMRPD3F0021, CMRPD3F0022, CMRPD3F0023, NARPD3J0021, NARPD3J0022, NARPD3L0061, 108-2410-H-182-008-MY2, 110-2410-H-182-013-MY3, WJY 2020-HR-01, WJY 2021-HR-01, WJY 2022-HR-01, WYJ 2021-AP-01, WYJ 2022-AP-01)
- Wang Jhan-Yang Public Trust Fund (CMRPG2F0081, CMRPG2F0082, CMRPG2F0083, CMRPD3F0021, CMRPD3F0022, CMRPD3F0023, NARPD3J0021, NARPD3J0022, NARPD3L0061, 108-2410-H-182-008-MY2, 110-2410-H-182-013-MY3, WJY 2020-HR-01, WJY 2021-HR-01, WJY 2022-HR-01, WYJ 2021-AP-01, WYJ 2022-AP-01)
This publication has 47 references indexed in Scilit:
- Plasma total and high molecular weight adiponectin levels and risk of coronary heart disease in womenAtherosclerosis, 2011
- Percent fat mass is inversely associated with bone mass and hip geometry in rural Chinese adolescentsJournal of Bone and Mineral Research, 2010
- Protective vascular and myocardial effects of adiponectinNature Clinical Practice Cardiovascular Medicine, 2008
- Cardiac Remodeling in ObesityPhysiological Reviews, 2008
- Serum Concentrations of Adiponectin and Risk of Type 2 Diabetes Mellitus and Coronary Heart Disease in Apparently Healthy Middle-Aged MenJACC, 2006
- Leptin, the obesity‐associated hormone, exhibits direct cardioprotective effectsBritish Journal of Pharmacology, 2006
- Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndromeJournal of Clinical Investigation, 2006
- CDC/AHA Workshop on Markers of Inflammation and Cardiovascular DiseaseCirculation, 2004
- Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease.Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1990
- CENTRAL OBESITY AND CORONARY HEART DISEASE IN MENThe Lancet, 1987